No. of patients (%)a |
---|
Variable | Multidayb | Non-multidayc |
P
|
---|
(n = 41) | (n = 172) |
---|
Age (year) |
Median (range) | 65(42–87) | 62(24–85) | |
< 65 | 20(49) | 99(58) | 0.38d |
Sex |
Male | 28(68) | 79(46) | 0.014d |
ECOG PS |
0 | 15(37) | 66(38) | 0.52e |
1 | 18(44) | 83(48) | |
2 | 7(17) | 16(9.3) | |
3 | 1(2.4) | 7(4.1) | |
CCr (mL/min)f |
Median (range) | 71.2(39.5–98.0) | 74.9(31.8–99.8) | |
< 50 | 3(7.3) | 18(11) | 0.77d |
T-Bil (mg/dL) |
Median (range) | 1.1(0.2–2.1) | 0.9(0.1–2.4) | |
< 2 | 39(95) | 162(94) | 1.0d |
FN rate of regimeng |
Low (< 10%) | 25(61) | 104(61) | 0.92e |
Moderate (10 to < 20%) | 13(32) | 52(30) | |
High (≥20%) | 3(7.3) | 16(9.3) | |
Stage |
II | 8(20) | 25(15) | 0.072e |
III | 9(22) | 71(41) | |
IV | 24(59) | 76(44) | |
CYP3A4 inhibitor |
Use | 6(15) | 22(13) | 0.80d |
MASCC score |
High risk (≤20) | 16(39) | 77(45) | 0.60d |
Blood culture |
Positive | 6(15) | 13(7.6) | 0.21d |
- aThe sum of the percentages may not equal 100% because of rounding off
- bThe multiday group included patients who were administered corticosteroid every day from the initiation of chemotherapy to onset of FN irrespective of its dosage
- cThe non-multiday group included patients who were administered corticosteroid without every day from the initiation of chemotherapy to onset of FN irrespective of its dosage
- dFisher’s exact test
- echi-squared test
- fThe values were calculated using the Cockcroft-Gault formula
- gEach rate was based on previous clinical studies [2,3,4,5,6]
- ECOG PS Eastern Cooperative Oncology Group performance status, CCr creatinine clearance, T-Bil total bilirubin, FN febrile neutropenia, CYP cytochrome P450, MASCC Multinational Association for Supportive Care in Cancer